New treatment approach for B-cell cancers using BTK degraders
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies
['FUNDING_R01'] · BAYLOR COLLEGE OF MEDICINE · NIH-10977353
This study is working on a new medication that aims to help people with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) by targeting a protein called BTK, which is important in these cancers, to make treatment more effective and overcome resistance to current therapies.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BAYLOR COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10977353 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new type of medication that targets Bruton’s Tyrosine Kinase (BTK), a key player in B-cell malignancies like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The approach involves creating a small molecule that can effectively degrade BTK, overcoming issues of resistance seen with current treatments. By targeting both the kinase and non-kinase functions of BTK, this therapy aims to provide a more effective treatment option for patients. The research includes laboratory studies to test the efficacy of these new agents in various B-cell cancer models.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with B-cell malignancies such as chronic lymphocytic leukemia or mantle cell lymphoma, especially those who have not responded to current treatments.
Not a fit: Patients with non-B-cell malignancies or those who are not currently undergoing treatment for B-cell cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for patients with B-cell malignancies, particularly those who have developed resistance to existing therapies.
How similar studies have performed: Previous research has shown promise in targeting BTK with covalent inhibitors, but this approach of using reversible covalent degraders is novel and has not been extensively tested.
Where this research is happening
HOUSTON, UNITED STATES
- BAYLOR COLLEGE OF MEDICINE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, JIN — BAYLOR COLLEGE OF MEDICINE
- Study coordinator: WANG, JIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.